SpringerLink
Log in

Perspectives in Antiinfective Therapy

Washington D.C., August 31 - September 3, 1988

  • Conference proceedings
  • © 1989
  • Latest edition

Overview

Editors:
  1. George Gee Jackson

    1. Department of Medical Microbiology, The London Hospital Medical College, London, Great Britain

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. H. D. Schlumberger

    1. Bayer AG, Pharma-Forschungszentrum, Wuppertal, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. H.-J. Zeiler

    1. Bayer AG, Pharma-Forschungszentrum, Wuppertal, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Bayer AG Centenary Symposium (BAYER)

  • 5331 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution

Other ways to access

Licence this eBook for your library

Institutional subscriptions

About this book

Pharmaceutical research has a long-standing tradition at Bayer since the establish­ ment of a Pharmaceutical Department 25 years after the foundation of the Farben­ fabriken of Friedrich Bayer & Co. in the city of Elberfeld, Germany. In 1888, one of the first antipyretic drugs, phenacetin, was synthesized. A milestone was marked by the discovery and launch of Aspirin TM in 1899, the most widely used and appreciated drug since then. The success of Bayer 205 (GermaninTM) in the treatment of slee** sickness led not only to the worldwide recognition of Bayer as a pharmaceutical company but also to intense research into antiinfective therapy. The antimalarial drugs Atebrin TM, Plasmochin TM and Resochin TM were the first of a whole series of significant contribu­ tions and even breakthroughs in the therapy of infections. The advances and the success of antibacterial therapy were heralded by the discovery of the antibacterial activity of the sulfonamides by Domagk, Klarer and Mietsch. The first drug of this class of compounds, Prontosil™, opened the new era of therapeutic control of bacterial infections. In 1939, Domagk received the Nobel Prize for Medicine for this breakthrough. A further breakthrough in the chemotherapy of the scourge of tuber­ culosis was achieved in 1946 by Domagk and his colleagues Behnisch, Mietzsch and Schmidt with the development of Conteben TM, followed shortly afterwards by the discovery of isoniazid (Neoteben TM) by Domagk, Offe and Siefken.

Similar content being viewed by others

Keywords

Table of contents (39 papers)

  1. Front Matter

    Pages I-XVII
    Download chapter PDF

  2. The Challenge of Perspective

    1. The Challenge of Perspective

      • G. G. Jackson
      Pages 1-4

  3. History and Philosophy of Bayer Parmaceutical Research

    1. History and Philosophy of Bayer Parmaceutical Research

      • W.-D. Busse
      Pages 5-11

  4. On Bacteriological Research

    1. On Bacteriological Research

      • R. Koch
      Pages 13-17

  5. Background to Robert Koch’s Lecture at the International Congress in Berlin, 1890

    1. Background to Robert Koch’s Lecture at the International Congress in Berlin, 1890

      • J. Parascandola
      Pages 19-21

  6. Classical Mechanisms of Antibacterial Drugs

    1. Front Matter

      Pages 23-23
      Download chapter PDF

    2. Multiple Penicillin Binding Protein Profiles in Penicillin Resistant Pneumococci: Evidence for the Clonal Nature of Resistance Among Clinical Isolates

      • A. Tomasz, D. Jabes, Z. Markiewicz, J. Garcia-Bustos, S. Nachman
      Pages 25-41

    3. Antibiotic Uptake into Gram-Negative Bacteria

      • R. E. W. Hancock, A. Bell
      Pages 42-53

    4. Inhibition of Protein Biosynthesis by Antibiotics

      • K. H. Nierhaus, R. Brimacombe, H. G. Wittmann
      Pages 54-72

    5. Inhibition of DNA Gyrase: Bacterial Sensitivity and Clinical Resistance to 4-Quinolones

      • M. E. Cullen, A. W. Wyke, F. McEachern, C. A. Austin, L. M. Fisher
      Pages 73-84

  7. Mechanisms of Nonbacterial Antiinfective Drugs

    1. Front Matter

      Pages 85-85
      Download chapter PDF

    2. Mechanisms of Antiretroviral Compounds in Inhibition of Viral and Cellular DNA Polymerases

      • K. Ono
      Pages 87-99

    3. Effects of Drugs on Lipids and Membrane Integrity of Fungi

      • N. H. Georgopapadakou
      Pages 100-111

    4. Membrane Changes Induced by Praziquantel

      • P. Andrews, A. Harder
      Pages 112-123

    5. Mechanisms of Action of Antimalarial Drugs

      • W. Peters
      Pages 124-143

  8. Pathogenic Microbial Mechanisms Susceptible to Drug Application

    1. Front Matter

      Pages 145-145
      Download chapter PDF

    2. Bacterial Adherence in Pathogenicity

      • S. Normark, S. Hultgren, B.-I. Marklund, G. Nyberg, A. Olsén, N. Strömberg et al.
      Pages 147-155

    3. Haemophilus influenzae Gene Expression and Bacterial Invasion

      • E. R. Moxon, J. S. Kroll, J. N. Weiser
      Pages 156-162

    4. Coordinate Regulation of Bacterial Virulence Genes

      • W. Goebel, J. Hacker
      Pages 163-174

  9. Microbial Drug Resistance

    1. Front Matter

      Pages 175-175
      Download chapter PDF
Back to top

Editors and Affiliations

  • Department of Medical Microbiology, The London Hospital Medical College, London, Great Britain

    George Gee Jackson

  • Bayer AG, Pharma-Forschungszentrum, Wuppertal, Germany

    H. D. Schlumberger, H.-J. Zeiler

Bibliographic Information

  • Book Title: Perspectives in Antiinfective Therapy

  • Book Subtitle: Washington D.C., August 31 - September 3, 1988

  • Editors: George Gee Jackson, H. D. Schlumberger, H.-J. Zeiler

  • Series Title: Bayer AG Centenary Symposium

  • DOI: https://doi.org/10.1007/978-3-642-46666-3

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1989

  • Softcover ISBN: 978-3-540-50964-6Due: 30 June 1989

  • eBook ISBN: 978-3-642-46666-3Published: 06 December 2012

  • Series ISSN: 1431-116X

  • Edition Number: 1

  • Number of Pages: XVII, 478

  • Topics: Internal Medicine

Publish with us

Policies and ethics

Back to top

Search

Navigation